Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

85
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
85
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

69
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
69
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

82
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
82
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

2.1K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
2.1K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

276
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
276
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

107
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining in vitro and ex vivo protein binding of levofloxacin and moxifloxacin in patients with TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

Heterogeneity of cartilage damage in Kellgren and Lawrence grade 2 and 3 knees: the MOST study.

Osteoarthritis and cartilage·2022
Same author

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

medRxiv : the preprint server for health sciences·2021
Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020
Same author

Evaluation of recorded video-observed therapy for anti-tuberculosis treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1.

Translational psychiatry·2018
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

High Throughput Single-cell and Multiple-cell Micro-encapsulation
16:19

High Throughput Single-cell and Multiple-cell Micro-encapsulation

Published on: June 15, 2012

19.3K

Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.

S H Browne1, C Peloquin2, F Santillo3

  • 1University of California, San Diego School of Medicine, Division of Infectious Diseases, San Diego, California, USA.

Clinical Pharmacology and Therapeutics
|June 10, 2017
PubMed
Summary
This summary is machine-generated.

Digitized medications using co-encapsulation (CoE) with ingestion sensors (IS) enable precise adherence tracking. This novel method ensures medication quality and accurate dosing histories for personalized therapy.

More Related Videos

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution
09:59

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

18.6K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

High Throughput Single-cell and Multiple-cell Micro-encapsulation
16:19

High Throughput Single-cell and Multiple-cell Micro-encapsulation

Published on: June 15, 2012

19.3K
Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution
09:59

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

18.6K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.3K

Area of Science:

  • Pharmaceutical Sciences
  • Biotechnology
  • Clinical Pharmacology

Background:

  • Accurate medication adherence monitoring is crucial for effective personalized drug therapy.
  • Existing methods for tracking oral medication intake lack precision.
  • A US Food and Drug Administration (FDA)-cleared system utilizes an edible ingestion sensor (IS) and wearable patch to record medication ingestion events.

Purpose of the Study:

  • To develop and validate a Good Manufacturing Practice (GMP) protocol for co-encapsulating (CoE) oral medications with an IS.
  • To assess the bioequivalence and in vitro dissolution profiles of CoE-IS medications compared to their native formulations.
  • To establish a method for generating "digitized-medications" for remote dosing history capture.

Main Methods:

  • Developed a GMP protocol for co-encapsulating oral medications with an IS within certified capsules.
  • Conducted a randomized bioequivalence study comparing CoE-IS-Rifamate to native Rifamate in 12 patients with active Mycobacterium tuberculosis.
  • Performed in vitro dissolution testing of CoE-IS medications across various biopharmaceutical classes according to USP and FDA guidelines.

Main Results:

  • The randomized study demonstrated bioequivalence between CoE-IS-Rifamate and native Rifamate in patients with active Mycobacterium tuberculosis.
  • In vitro dissolution testing confirmed that CoE-IS medications met USP specifications and were equivalent to their native formulations.
  • The CoE process successfully integrated the IS without compromising the quality of the original oral medications.

Conclusions:

  • Co-encapsulation (CoE) is a viable method to combine oral medications with ingestion sensors (IS) without altering drug quality.
  • This technology generates "digitized" medications capable of remote dosing history capture, enhancing medication adherence monitoring.
  • CoE facilitates personalized drug therapy through high-resolution, accurate measurement of medication adherence.